synthetic peptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-02-28 and is reviewed periodically as new material appears.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | ≈889 Da for the 7-residue fragment | Full-length thymosin beta-4 is ≈4.9 kDa; catalogs differ |
| Appearance | White to off-white powder | Hygroscopic; weight shifts with residual moisture |
| Solubility class | Freely soluble in water | Also dissolves in aqueous buffers; poorly soluble in nonpolar solvents |
| Typical storage temperature | −20 °C, desiccated, protected from light | Once rehydrated, short-term holding at 2-8 °C |
| Typical analytical method | Reversed-phase HPLC with mass spectrometry | Purity by UV absorbance; identity by ESI-MS or MALDI-TOF |
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
The virus has been used for cyber warfare against the national oil companies Saudi Aramco and Qatar's RasGas. Saudi Aramco announced the attack on their Facebook page and went offline again until a company statement was issued on 25 August 2012. The statement falsely reported normal business was resumed on 25 August 2012. However a Middle Eastern journalist leaked photographs taken on 1 September 2012 showing kilometers of petrol trucks unable to be loaded due to backed business systems still inoperable. On 29 August 2012 the same attackers behind Shamoon posted another pastie on PasteBin.com, taunting Saudi Aramco with proof they still retained access to the company network. The post contained the username and password on security and network equipment and the new password for the CEO Khalid Al- Falih The attackers also referenced a portion of the Shamoon malware as further proof in the pastie. According to Kubecka, in order to restore operations. Saudi Aramco used its large private fleet of aircraft and available funds to purchase much of the world's hard drives, driving the price up. New hard drives were required as quickly as possible so oil prices were not affected by speculation. By 1 September 2012 gasoline resources were dwindling for the public of Saudi Arabia 17 days after the 15 August attack. RasGas was also affected by a different variant, crippling them in a similar manner.
Sickle cell disorders, which are the most prevalent form of hemoglobinopathy. Sickle hemoglobin (HbS) is prone to polymerize when deoxygenated, precipitating within the red blood cell. This damages the RBC membrane resulting in its premature destruction and consequent anemia. Unstable hemoglobin variants are mutations that cause the hemoglobin molecule to precipitate, spontaneously or upon oxidative stress, resulting in hemolytic anemia. Precipitated, denatured hemoglobin can attach to the inner layer of the plasma membrane of the red blood cell (RBC) forming Heinz bodies, leading to premature destruction of the RBC and anemia. Change in oxygen affinity. High or low oxygen affinity hemoglobin molecules are more likely than normal to adopt the relaxed (R, oxy) state or the tense (T, deoxy) state, respectively. High oxygen affinity variants (R state) cause polycythemia (e.g., Hb Chesapeake, Hb Montefiore). Low oxygen affinity variants can cause cyanosis (e.g., Hb Kansas, Hb Beth Israel).
The causes of hirsutism can be divided into endocrine imbalances and non-endocrine etiologies. It is important to begin by first determining the distribution of body hair growth. If hair growth follows a male distribution, it could indicate the presence of increased androgens or hyperandrogenism. However, there are other hormones not related to androgens that can lead to hirsutism. A detailed history is taken by a provider in search of possible causes for hyperandrogenism or other non-endocrine-related causes. If the distribution of hair growth occurs throughout the body, this is referred to as hypertrichosis, not hirsutism.
=== 1981: reconstitution === In March 1981, the Minister for the Arts and Minister for Educational Services, Norman Lacy, had the Victorian College of the Arts Act passed through the Victorian Parliament. Its purpose was the reconstitution of the Victorian College of the Arts (VCA) made necessary by the repeal in 1980 of the Victorian Institute of Colleges Act and to make it "better able to provide for the preparation of young people to enter upon careers as professional artists. It also represented a significant development for the Victorian Arts Centre." Lacy laid out a rationale for the re-constitution of the college under a VCA specific act which was derived firstly "from the quite specific demands and circumstances of preparing young artists for professional practise." He asserted that "the basic concept upon which the college is built is that young artists intending to enter careers as practitioners in their various fields are best assisted to achieve their ambitions in a milieu of continuous artistic activity and endeavour of a fully professional nature. To the extent that artistic education is separated from normal professional practice it is so much less effective." Secondly, the rationale related to the adjacent location of the VCA campus to the National Gallery of Victoria and the Victorian Arts Centre. He said that this "Greater Arts Centre concept is central to the government's decision to reconstitute the college by separate statute as well as to the development of the arts in general.
Sources: en.wikipedia.org
=== Secondary neoplasm === Development of secondary neoplasia after successful chemotherapy or radiotherapy treatment can occur. The most common secondary neoplasm is secondary acute myeloid leukemia, which develops primarily after treatment with alkylating agents or topoisomerase inhibitors. Survivors of childhood cancer are more than 13 times as likely to get a secondary neoplasm during the 30 years after treatment than the general population. Not all of this increase can be attributed to chemotherapy.
The force is only dependent on the charge and electric field strength. The lighter ions will be deflected more and heavier ions less due to the difference in inertia and the ions will physically separate from each other in space into distinct beams of ions as they exit the electric sector. And the force on an ion in a linear homogenous magnetic field (a magnetic sector) is:
Osavampator (developmental code names TAK-653 and NBI-1065845) is an experimental drug being investigated as a treatment for treatment-resistant depression. It is being developed by Neurocrine Biosciences and Takeda Pharmaceuticals (Millennium Pharmaceuticals, Inc.). Takeda Pharmaceuticals discovered the molecule originally, and holds exclusive right to market the drug in Japan, while Neurocrine Biosciences holds the right to market it to the rest of the world.
Sources: en.wikipedia.org
Through the Luebering–Rapoport pathway bisphosphoglycerate mutase catalyzes the transfer of a phosphoryl group from C1 to C2 of 1,3-BPG, giving 2,3-BPG. 2,3-bisphosphoglycerate, the most concentrated organophosphate in the erythrocyte, forms 3-PG by the action of bisphosphoglycerate phosphatase. The concentration of 2,3-BPG varies proportionately with the pH, since it is inhibitory to catalytic action of bisphosphoglycerate mutase. Under physiological conditions, the flux through the Rapoport-Luebering shunt is 19% of the main glycolytic flux.
Since this series was only discovered and studied in 1947–1948, its nuclides were never given historic names. Each of the other series have many of their nuclides given historical names. This series has an isotope of radon only produced in a rare branch (not shown in the illustration) but not in the main decay sequence. Other series produce radon in the main decay sequence, which, if occurring in mineral, would tend to migrate through the mineral and be released as radioactive gas. This series ends in thallium (or, practically speaking, bismuth) rather than lead. Its parent nuclides are essentially extinct, explaining why the series was discovered much later, after the development of artificial nucleosynthesis. Each of the other series have primordial parent nuclides. The total energy released from neptunium-237 to thallium-205, including the energy lost to neutrinos, is 49.29 MeV; from californium-249, 66.87 MeV. As the energy of the final step from bismuth to thallium, though known, will not be available until the inconceivable future, it may be better to quote the figures 46.16 MeV and 63.73 MeV to bismuth-209.
Primary treatment for wastewater or drinking water includes settling in a sedimentation chamber to remove as much of the solid matter as possible before applying additional treatments. The amount removed is controlled by the hydraulic residence time (HRT). When water flows through a volume at a slower rate, less energy is available to keep solid particles entrained in the stream and there is more time for them to settle to the bottom. Typical HRTs for sedimentation basins are around two hours, although some groups recommend longer times to remove micropollutants such as pharmaceuticals and hormones. Disinfection is the last step in the tertiary treatment of wastewater or drinking water. The types of pathogens that occur in untreated water include those that are easily killed like bacteria and viruses, and those that are more robust such as protozoa and cysts. The disinfection chamber must have a long enough HRT to kill or deactivate all of them.
Sources: en.wikipedia.org
Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.
The name is a commercial label rather than a systematic chemical designation, so different vendors and papers attach it to different sequences. Some treat it as a fragment and others as the whole protein. Comparing two reports therefore requires checking what each one actually analyzed.
Typically it reflects the relative area of the main peak in a reversed-phase chromatogram at a given wavelength. It does not confirm the amino acid sequence, the counter-ion, or the amount of peptide by mass. Identity is normally established by a separate mass measurement.
No. Thymosin beta-4 is a 43-residue protein, while TB-500 refers to a seven-residue fragment corresponding to its N-terminal region. The two names are often used loosely in commercial and community writing, which obscures the difference in size, sequence, and likely behavior.